Results overview: Found 6 records in 0.02 seconds.
Articles, 6 records found
Articles 6 records found  
1.
33 p, 2.0 MB Diagnosis and management of AML in adults : 2022 recommendations from an international expert panel on behalf of the ELN / Döhner, Hartmut (Ulm University Hospital. Department of Internal Medicine III) ; Wei, Andrew H. (Peter MacCallum Cancer Centre. Royal Melbourne Hospital and University of Melbourne. Department of Haematology) ; Appelbaum, Frederick (University of Washington. Fred Hutchinson Cancer Research Center) ; Craddock, Charles (Centre for Clinical Haematology. Queen Elizabeth Hospital. University of Birminham) ; DiNardo, Courtney D. (The University of Texas MD Anderson Cancer Center. Department of Leukemia) ; Dombret, Hervé (Saint-Louis Institute for Research. Université de Paris. Hôpital Saint-Louis. Assistance Publique-Hôpitaux de Paris. Department of Hematology) ; Ebert, Benjamin L. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Fenaux, P. (Service d'Hématologie Séniors. Hôpital Saint-Louis. Assistance Publique-Hôpitaux de Paris) ; Godley, Lucy A. (The University of Chicago. Section of Hematology/Oncology. Department of Medicine) ; Hasserjian, Robert P (Massachusetts General Hospital) ; Larson, Richard A (University of Chicago. Department of Medicine and Comprehensive Cancer Center) ; Levine, Ross L. (Memorial Sloan Kettering Cancer Center. Human Oncology and Pathogenesis Program and Leukemia Service. Department of Medicine) ; Miyazaki, Yasushi (Atomic Bomb Disease Institute. Nagasaki University. Department of Hematology) ; Niederwieser, Dietger (University of Leipzig) ; Ossenkoppele, Gert (Department of Haematology. Amsterdam UMC. Location VU University Medical Center) ; Röllig, Christoph (Department of Internal Medicine I. University Hospital Carl Gustav Carus TU Dresden) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Stein, Eytan M. (Leukemia Service. Department of Medicine. Memorial Sloan Kettering Cancer Center) ; Tallman, Martin S. (Leukemia Service. Department of Medicine. Memorial Sloan Kettering Cancer Center) ; Tien, Hwei-Fang F. (Division of Hematology. Department of Internal Medicine. National Taiwan University Hospital) ; Wang, Jianxiang (Institute of Hematology and Blood Diseases Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College) ; Wierzbowska, Agnieszka (Department of Hematology. Medical University of Lodz) ; Löwenberg, Bob (Department of Hematology. Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute)
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. [...]
2022 - 10.1182/blood.2022016867
Blood, Vol. 140 Núm. 12 (september 2022) , p. 1345-1377  
2.
7 p, 363.5 KB The EHA Research Roadmap : Malignant Myeloid Diseases / Döhner, Hartmut (Department of Internal Medicine III. Ulm University Hospital) ; Malcovati, Luca (Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)) ; Ossenkoppele, Gert J. (Amsterdam UMC. Department of Hematology. VU University. Medical Center) ; Hochhaus, Andreas (Universitätsklinikum Jena. Klinik für Innere Medizin II. Hämatologie/Onkologie) ; Maria Vannucchi, Alessandro (Center Research and Innovation of Myeloproliferative Neoplasms. CRIMM. University of Florence) ; Bullinger, Lars (Freie Universität Berlin) ; Cervantes, Francisco (Hospital Clínic i Provincial de Barcelona) ; Craddock, Charles (Centre for Clinical Haematology. Queen Elizabeth Hospital) ; de Witte, Theo. (Radboud University. Medical Centre. Nijmegen) ; Döhner, Konstanze (Department of Internal Medicine III. Ulm University Hospital) ; Dombret, Hervé (Institut de Recherche Saint-Louis (IRSL). Université de Paris. Hôpital Saint-Louis) ; Fenaux, Pierre (Département (DMU) d'Hématologie et Immunologie. Assistance Publique Hôpitaux de Paris. Hôpital St Louis. Université de Paris) ; Geissler, Jan (Leukemia Patient Advocates Foundation) ; Germing, Ulrich (Klinik für Hämatologie. Onkologie und Klinische Immunologie. Universitätsklinikum Düsseldorf. Heinrich-Heine Universität Düsseldorf) ; Guilhot, Francois (University of Poitiers) ; Harrison, Claire (Department of Haematology. Guys and St thomas'Hospital) ; Hellström-Lindberg, Eva (Karolinska Institutet (Estocolm, Suècia)) ; Passamonti, Francesco (Department of Clinical and Biological Sciences. University of Turin. San Luigi University Hospital) ; Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Skoda, Radek (University Hospital Basel (Basilea, Suïssa)) ; Wierzbowska, Agnieszka. (Multi-specialized Center of Oncology and Traumatology)
In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. [...]
2021 - 10.1097/HS9.0000000000000635
HemaSphere, Vol. 5 Núm. 9 (2021)  
3.
6 p, 186.9 KB Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab / Topp, Max S. (Universitätsklinikum Würzburg) ; Gökbuget, Nicola (Goethe University) ; Zugmaier, Gerhard (Amgen GmbH) ; Stein, Anthony S. (Gehr Family Center for Leukemia Research. City of Hope) ; Dombret, Hervé (Saint Louis Hospital. University of Paris) ; Chen, Yuqi (Amgen. Inc) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg) ; Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Kantarjian, H. M. (The University of Texas MD Anderson Cancer Center) ; Universitat Autònoma de Barcelona
Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. [...]
2021 - 10.1002/cncr.33298
Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559  
4.
7 p, 171.0 KB Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia / Rambaldi, Alessandro (Department of Oncology and Hematology. University of Milan) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Kantarjian, H. M. (Department of Leukemia. University of Texas MD Anderson Cancer Center) ; Dombret, Hervé (Department of Hematology. Hopital Saint-Louis. Paris Diderot University) ; Ottmann, O. G. (Division of Cancer and Genetics. School of Medicine. Cardiff University) ; Stein, A. S. (Gehr Family Center for Leukemia Research. City of Hope) ; Tuglus, C. A. (Amgen. Inc) ; Zhao, X. (Amgen. Inc) ; Kim, C. (Amgen. Inc) ; Martinelli, Giovanni (Scientific Institute of Romagna for the Study and Treatment of Cancer) ; Universitat Autònoma de Barcelona
Background: A single-arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T-cell-engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limited treatment options. [...]
2020 - 10.1002/cncr.32558
Cancer, Vol. 126 Núm. 2 (15 2020) , p. 304-310  
5.
13 p, 2.7 MB Minimal residual disease level predicts outcome in adults with Ph-negative Bprecursor acute lymphoblastic leukemia / Gökbuget, Nicola (University Hospital of Frankfurt (Alemanya)) ; Dombret, Hervé (Hôpital Saint-Louis, Université Paris Diderot) ; Giebel, Sebastian (Maria Sklodowska Curie Memorial Cancer Center, Gliwice) ; Bruggemann, Monika (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Foà, Robin (Sapienza University of Rome) ; Hoelzer, Dieter (University Hospital of Frankfurt (Alemanya)) ; Kim, Christopher (Amgen Inc, Thousand Oaks, CA, USA) ; Martinelli, Giovanni (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ; Parovichnikova, Elena (National Research Center for Hematology, Moscow) ; Rambaldi, Alessandro (Dipartimento di Oncologia ed Ematologia, Università degli Studi di Milano and Ospedale Papa Giovanni XXIII) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Schoonen, Marieke (Amgen Ltd, London) ; Stieglmaier, Julia M. (Amgen GmBH, Munich) ; Zugmaier, Gerhard (Amgen GmBH, Munich) ; Bassan, Renato (Ospedale dell'Angelo, Mestre-Venezia) ; Universitat Autònoma de Barcelona
Objectives: Detectable minimal residual disease (MRD) after therapy for acute lymphoblastic leukemia (ALL) is the strongest predictor of hematologic relapse. This study evaluated outcomes of patients with B-cell precursor ALL with MRD of ≥10−4. [...]
2019 - 10.1080/16078454.2019.1567654
Hematology, Vol. 24 Núm. 1 (2019) , p. 337-348  
6.
7 p, 444.1 KB Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia / Gökbuget, N. (Goethe University. University Hospital Frankfurt) ; Kelsh, M. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Chia, V. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Advani, Anjali (Cleveland Clinic (Estats Units d'Amèrica)) ; Bassan, Renato (Ospedale dell'Angelo (Venècia, Itàlia)) ; Dombret, Hervé (Hôpital Saint-Louis (Paris, França)) ; Doubek, Michael (University Hospital Brno (República Txeca)) ; Fielding, A. K. (UCL Cancer Institute (Londres, Regne Unit)) ; Giebel, S. (Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology (Polònia)) ; Haddad, V. (Amgen Ltd. (Uxbridge, Regne Unit)) ; Hoelzer, Dieter (Goethe University. University Hospital Frankfurt) ; Holland, C. (Amgen Ltd. (Rockville, Estats Units d'Amèrica)) ; Ifrah, N. (Centre Hospitalier Universitaire (Angers, França)) ; Katz, A. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Maniar, T. (Amgen (Thousand Oaks, Estats Units d'Amèrica)) ; Martinelli, Giovanni (Policlinico Sant'Orsola-Malpighi (Bolònia, Itàlia)) ; Morgades, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; O'Brien, Susan (University of Texas MD Anderson Cancer Center (Houston, Texas)) ; Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rowe, J. M. (Rambam Medical Center) ; Stein, Anthony (City of Hope National Medical Center (Duarte, Estats Units d'Amèrica)) ; Topp, M. (Universitätsklinikum Würzburg (Alemanya)) ; Wadleigh, M. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Kantarjian, H. (University of Texas MD Anderson Cancer Center (Houston, Texas))
We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. [...]
2016 - 10.1038/bcj.2016.84
Blood Cancer Journal, Vol. 6, Núm. 9 (September 2016) , p. e473  

See also: similar author names
1 Dombret, H
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.